Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders.
Bischofberger
N
N
Gilead Sciences, Inc., Foster City, California 94404, USA.
Jacobson
K A
KA
von Lubitz
D K
DK
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D000818:Animals; D001921:Brain / Q000502:physiology* / Q000503:physiopathology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000503:physiopathology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D018696:Neuroprotective Agents; D058906:Purinergic P1 Receptor Agonists
D018696:Neuroprotective Agents; D058906:Purinergic P1 Receptor Agonists; C106045:adenosine amine congener; D000241:Adenosine